

#### **Lung Cancer Screening**

Luis E. Raez MD FACP FCCP President Florida Society of Clinical Oncology (FLASCO) Chief Scientific Officer& Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim College of Medicine Florida International University

## Lung Cancer Screening.....


"...the opportunity to realize the greatest single reduction of cancer mortality in the history of the war on cancer."

James Mulshine, MD Associate Provost and Vice President for Research Rush University Medical Center


#### Cancer Statistics, 2018

American Cancer Society Cancer Facts & Figures, 2018


#### Estimated Cancer Cases, Florida, 2018



#### Estimated Cancer Deaths, Florida, 2018



#### **History of Lung Cancer Screening**



#### Prevention and Early Diagnosis of Lung Cancer

Supplement to Cancer

#### **The Mayo Lung Project**

A Perspective

Robert S. Fontana, M.D.	BACKGROUND. The Mayo Lung Project (MLP) was a randomized, controlled, cl			
	ical trial designed to determine whether intensive radiologic and cytologic screen-			
Department of Medicine, Mayo Clinic, Rochester,	ing for lung carcinoma could reduce lung carcinoma mortality significantly.			
Minnesota.	METHODS. Half the MLP population was encouraged (and reminded) to undergo			
	free chest X-rays and free sputum cytology tests every 4 months for 6 years,			


#### Cancer, 2000

1971 – 1983 N = 9211 men, heavy smokers


> Randomized: CxR + sputum q 4 months CxR + sputum annually

#### Mayo Lung Project: Results

#### Lung Ca Survival



#### **Cumulative Lung Ca Deaths**




#### **ONLINE FIRST**


#### Screening by Chest Radiograph and Lung Cancer Mortality The Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Trial

Martin M. Oken, MD Willam G. Hocking, MD	<b>Context</b> The effect on mortality of screening for lung cancer with modern chest ra- diographs is unknown.
Paul A. Kvale, MD	<b>Objective</b> To evaluate the effect on mortality of screening for lung cancer using ra- diographs in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Gerald L. Andriole, MD	diographs in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Saundra S. Buys, MD	Design, Setting, and Participants Randomized controlled trial that involved 154901

JAMA, 2011




#### Stage of discovered NSCLCs:



#### PLCO: Results

#### **Cumulative Lung Cancer Deaths**



#### Early Lung Cancer Action Project: overall design and findings from baseline screening

Claudia I Henschke, Dorothy I McCauley, David F Yankelevitz, David P Naidich, Georgeann McGuinness, Olli S Miettinen, Daniel M Libby, Mark W Pasmantier, June Koizumi, Nasser K Altorki, James P Smith

#### Summary

**Background** The Early Lung Cancer Action Project (ELCAP) is designed to evaluate baseline and annual repeat screening by low-radiation-dose computed tomography (low-dose CT) in people at high risk of lung cancer. We report the baseline experience.

**Methods** ELCAP has enrolled 1000 symptom-free volunteers, aged 60 years or older, with at least 10 packyears of cigarette smoking and no previous cancer, who were medically fit to undergo thoracic surgery. After a structured interview and informed consent, chest radiographs and lowdose CT were done for each participant. The diagnostic Interpretation Low-dose CT can greatly improve the likelihood of detection of small non-calcified nodules, and thus of lung cancer at an earlier and potentially more curable stage. Although false-positive CT results are common, they can be managed with little use of invasive diagnostic procedures.

Lancet 1999; 354: 99–105 See Commentary page

#### Introduction

In the USA in 1998, there were an estimated 160 000 deaths from lung cancer and an estimated 172 000 new

N = 1000 Age 60 and over 10 pack-year smoking history CxR + low dose Chest CT Lancet, 1999

#### **ELCAP:** Results

#### Discovered Lung Cancers:

Stage	СТ	CxR
Ι	23	4
II	1	1
III	3	2


## Problems with Screening Trials:

• Overdiagnosis


Diagnosis of cancers that would have never become clinically significant



















**U.S. Preventive Services Task Force** 

Division of the Agency for Healthcare Research and Quality (AHRQ)

"The USPSTF concludes that the <u>evidence is insufficient</u> to recommend for or against screening asymptomatic persons...."

Lung Cancer Screening Recommendations (2004)

www.uspreventiveservicestaskforce.org

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

#### Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

The National Lung Screening Trial Research Team\*

NEJM, June, 2011

33 Sites \$300,000,000

## National Lung Screening Trial

- Age 55-75 years
- >30 pack-year smoking history
- Enrolled between 2002-2004
- Annual scans (T0, T1 and T2)
- >4 mm considered positive test

Modality	Ν
Chest CT*	26,722
Chest x-ray	26,732

NEJM, June, 2011

## NLST: Key Findings

#### 20% reduction in deaths from lung cancer


## NLST: Key Findings

#### 20% reduction in deaths from lung cancer

6.6% reduction in overall mortality

#### Cumulative Lung Cancers


Cumulative Deaths from Lung Cancer




NEJM, June 2011

#### NLST: Stage Shift

#### Stage at Diagnosis:



## NLST: CT Findings



- Lung cancer incidence = 645/100,000 person-years
- 96% of positive findings were not cancer

#### LUNG CANCER SCREENING

DOI: 10.1377/hlthaff.2011.0814 HEALTH AFFAIRS 31, NO. 4 (2012): 770-779 ©2012 Project HOPE— The People-to-People Health Foundation, Inc. By Bruce S. Pyenson, Marcia S. Sander, Yiding Jiang, Howard Kahn, and James L. Mulshine

#### An Actuarial Analysis Shows That Offering Lung Cancer Screening As An Insurance Benefit Would Save Lives At Relatively Low Cost

Bruce S. Pyenson (bruce .pyenson@milliman.com) is a principal and consulting actuary in the consulting firm Milliman, in New York City.

Marcia S. Sander is a principal and consulting actuary in the New York office of Milliman.

Yiding Jiang is a consulting actuary in the New York

ABSTRACT Lung cancer screening is not established as a public health practice, yet the results of a recent large randomized controlled trial showed that screening with low-dose spiral computed tomography reduces lung cancer mortality. Using actuarial models, this study estimated the costs and benefits of annual lung cancer screening offered as a commercial insurance benefit in the high-risk US population ages 50–64. Assuming current commercial reimbursement rates for treatment, we found that screening would cost about \$1 per insured member per

#### Age 50-64 years, >30 pack-year smoking history


Health Affairs, April 2012

## Cost per Life-year Saved

Type of Cancer	Screening Technique	Cost per life-year saved (2012 dollars)	
Cervical	Pap smear	50,162	
Colorectal	Colonoscopy	18,705	
Breast	Mammography	31,309	
Lung	Low-dose chest CT	11,708 – 26,016	

- Randomized European trial
- 10 year results presented at IASLC 2018 meeting
- N = 15, 792

Modality	Ν
Chest CT	7,900
No screen	7,892



- LDCT
- Indeterminate: 2 month f/u for volume doubling time

#### **Results:**

- Follow-up at 10 years for 93.7% of participants
- 86% compliance rate
- False positive rate = 59.4%

Overall lung cancer detection rate = 3.2%

Baseline	1 year	3 years	5 ½ years
0.9%	.08%	1.1%	0.8%

#### Results – Lung Cancer Deaths:

214 study arm vs. 157 control arm

LC mortality rate-ratio:

- Men = 0.74 (p = 0.0003)
- Women = 0.61 (p = 0.0054)

## Low-dose Spiral Chest CT



- Single breath-hold
- No iv contrast

#### **Radiation Exposure**

Test	Radiation (mSv)
Transatlantic flight	0.1
Mammogram	0.7
LDCT	<1
Lumbar Spine series	2
Diagnostic chest CT	10
CT Abd/pelvis	25
Background/yr	3
Background /yr- Colorado	4.5
Occupational Exposure	50

"Risks of medical imaging at effective doses below 50 mSv are too low to be detectable and may be non-existent."

Am Assoc of Physicists in Medicine

#### NCCN Guidelines - 2018

- Age 55 74 y, and
- $\geq$  30 pack-year history of smoking, and
- Smoking cessation < 15 years

#### or

- Age > 50 y, and
- $\geq$  20 pack-year history of smoking, and
- Additional risk factors\*

- \* Risk factors
- Personal cancer history
- Family history of lung cancer
- Chronic lung disease (COPD, ILD)
- Carcinogen exposure (Asbestos, radon, arsenic, etc.)

# Screening for Lung Cancer: U.S.DRAFTPreventive Services Task ForceDRAFTRecommendation StatementDRAFTDRAFTDRAFT

## Summary of Recommendation and Evidence

The U.S. Preventive Services Task Force (USPSTF) recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in persons at high risk for lung cancer based on age and smoking history.

This is a Grade B recommendation.

July 30, 2013

DRAFT

#### Annals of Internal Medicine

CLINICAL GUIDELINE

#### Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement

Virginia A. Moyer, MD, MPH, on behalf of the U.S. Preventive Services Task Force\*

Description: Update of the 2004 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for lung cancer.

Methods: The USPSTF reviewed the evidence on the efficacy of low-dose computed tomography, chest radiography, and sputum cytologic evaluation for lung cancer screening in asymptomatic persons who are at average or high risk for lung cancer (current or former smokers) and the benefits and harms of these screening tests and of surgical resection of early-stage non-small cell lung cancer. The USPSTF also commissioned modeling studies to provide information about the optimum age at which to begin and end screening, the optimum screening interval, and the relative benefits and harms of different screening strategies.

Population: This recommendation applies to asymptomatic adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have guit within the past 15 years. Recommendation: The USPSTF recommends annual screening for lung cancer with low-dose computed tomography in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. (B recommendation)

Ann Intern Med.

For author affiliation, see and of text.

 For a list of the members of the USPSTF, see the Appandix (available at www.amab.org).


This article was published online first at www.armals.org on 21 December 2012.



THE DESIGN OF

#### 2013 – ACR Accreditation 2018 – Formal program launched

- FTE ARNP
- Shared decision making visit
- Letters to patients/physicians
- "Open" program



**Annual Volume** 

Interval	Lung- RADS 3	Lung- RADS 4	Positive Biopsy
10/2018 — 12/2018	4	6	2
1/2019 — 2/2019	4	3	

**Challenges:** 

- Legal HIPAA
- "Open" program makes management difficult

## Screening for lung cancer saves lives...

## Needs to be done in a well-organized program, and

...along with smoking cessation.

# "...the opportunity to realize the greatest single reduction of cancer mortality in the history of the war on cancer."

James Mulshine, MD Associate Provost and Vice President for Research Rush University Medical Center